Matthew Lowell Meizlish, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neutrophil Activation | 1 | 2021 | 180 | 0.700 |
Why?
|
| Extracellular Matrix | 1 | 2024 | 1720 | 0.530 |
Why?
|
| Macrophages | 2 | 2024 | 5753 | 0.390 |
Why?
|
| Aspirin | 1 | 2021 | 3129 | 0.320 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2021 | 2746 | 0.320 |
Why?
|
| Hospital Mortality | 1 | 2021 | 5295 | 0.280 |
Why?
|
| Anticoagulants | 1 | 2021 | 4795 | 0.250 |
Why?
|
| Fibroblasts | 2 | 2024 | 4137 | 0.210 |
Why?
|
| Inflammation | 1 | 2021 | 10759 | 0.180 |
Why?
|
| Scleroderma, Systemic | 1 | 2024 | 345 | 0.170 |
Why?
|
| Integrins | 1 | 2024 | 835 | 0.170 |
Why?
|
| Cytoskeleton | 1 | 2024 | 1169 | 0.160 |
Why?
|
| Receptors, Immunologic | 1 | 2024 | 1408 | 0.150 |
Why?
|
| Blood Coagulation Disorders | 1 | 2020 | 350 | 0.140 |
Why?
|
| Organizations | 1 | 2018 | 172 | 0.140 |
Why?
|
| Fibrosis | 1 | 2024 | 2051 | 0.140 |
Why?
|
| Collagen | 1 | 2024 | 2635 | 0.130 |
Why?
|
| Patient Advocacy | 1 | 2017 | 358 | 0.120 |
Why?
|
| Vascular Diseases | 1 | 2020 | 1160 | 0.100 |
Why?
|
| Critical Illness | 2 | 2021 | 2724 | 0.090 |
Why?
|
| Politics | 1 | 2017 | 814 | 0.090 |
Why?
|
| Physician's Role | 1 | 2017 | 920 | 0.090 |
Why?
|
| Homeostasis | 1 | 2021 | 3320 | 0.080 |
Why?
|
| Mice, Knockout | 1 | 2024 | 14392 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2020 | 4420 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1089 | 0.070 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2017 | 1186 | 0.070 |
Why?
|
| Cell Proliferation | 1 | 2022 | 10422 | 0.070 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 18220 | 0.060 |
Why?
|
| Meningioma | 1 | 2013 | 1216 | 0.060 |
Why?
|
| Meningeal Neoplasms | 1 | 2013 | 1246 | 0.060 |
Why?
|
| Signal Transduction | 2 | 2024 | 23416 | 0.060 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 3885 | 0.050 |
Why?
|
| Prognosis | 2 | 2021 | 29687 | 0.050 |
Why?
|
| Bleomycin | 1 | 2024 | 495 | 0.050 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 15841 | 0.050 |
Why?
|
| Cross-Sectional Studies | 2 | 2021 | 26071 | 0.050 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 3093 | 0.050 |
Why?
|
| Incidence | 1 | 2021 | 21365 | 0.050 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 3215 | 0.050 |
Why?
|
| Hospitalization | 1 | 2021 | 10707 | 0.050 |
Why?
|
| B-Lymphocytes | 1 | 2013 | 4744 | 0.040 |
Why?
|
| Aged | 3 | 2021 | 169288 | 0.040 |
Why?
|
| Physicians | 1 | 2018 | 4584 | 0.040 |
Why?
|
| Aged, 80 and over | 2 | 2021 | 58952 | 0.040 |
Why?
|
| Cell Count | 1 | 2022 | 1831 | 0.040 |
Why?
|
| Middle Aged | 3 | 2021 | 220853 | 0.040 |
Why?
|
| Adult | 3 | 2021 | 221119 | 0.040 |
Why?
|
| Male | 4 | 2024 | 360693 | 0.030 |
Why?
|
| Humans | 7 | 2024 | 761208 | 0.030 |
Why?
|
| T-Lymphocytes | 1 | 2013 | 10203 | 0.030 |
Why?
|
| Animals | 3 | 2024 | 168079 | 0.030 |
Why?
|
| Female | 4 | 2024 | 392544 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 1963 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2021 | 80674 | 0.020 |
Why?
|
| Skin | 1 | 2024 | 4473 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2024 | 18926 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3744 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 6124 | 0.020 |
Why?
|
| Pandemics | 1 | 2020 | 8663 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 39126 | 0.010 |
Why?
|
| Mice | 1 | 2024 | 81326 | 0.010 |
Why?
|
| Young Adult | 1 | 2020 | 59221 | 0.010 |
Why?
|
| United States | 1 | 2017 | 72339 | 0.010 |
Why?
|